Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2008

PharmAthene Retains GTC’s Manufacturing Services for Protexia

  • GTC Biotherapeutics will continue to conduct process development and clinical manufacturing services for PharmAthene’s Protexia® program. The manufacturing work is planned to conclude in the third quarter.

    Protexia is being developed as a pre- and postexposure therapy for victims of a chemical nerve agent attack. It is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »